Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172788432> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3172788432 abstract "Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease. NAFLD's initial phase involves hepatic steatosis (triglyceride accumulation in hepatocytes). NAFLD can rapidly progress to non-alcoholic steatohepatitis (NASH). NASH is characterized by increased oxidative stress, lipid peroxidation, inflammation, mitochondria dysfunction, and hepatocyte death and fibrosis. If untreated, NASH leads to cirrhosis, and in some cases, hepatocellular carcinoma. Besides lifestyle modifications (e.g., diet and exercise), we still do not have effective treatment for NASH today. Therefore, it is critical to understand the mechanisms responsible for NAFLD progression to NASH to develop efficient therapies and find disease progression biomarkers. Signaling lymphocytic activation molecule 1 (SLAMF1) protein is a self-ligand receptor involved in regulating the immune response to viruses and cancer. In the present project, we found that hepatocytes from NASH liver samples from humans and mice express high levels of SLAMF1. To confirm these findings, we used palmitic acid-treated HepG2 hepatocytes as an “in vitro” model of NASH. We found that palmitic acid treatment of HepG2 hepatocytes leads to significant increases in SLAMF1 mRNA and protein levels, which correlated with an increased hepatocyte death in response to palmitic acid treatment. To investigate the potential role of SLAMF1 in mediating the toxic effects of palmitic acid treatment, we partially blocked SLAMF1 with siRNA. Our results showed that downregulation of SLAMF1 levels in hepatocytes significantly improved cell viability and reduced the expression of the cytotoxicity and proapoptotic markers such as cleaved caspase 3 and vimentin V by hepatocytes. We also found that palmitic acid-treated hepatocytes secrete SLAMF1 in the culture medium. Our data suggest that SLAMF1, both membrane-bound and soluble form, are upregulated by palmitic acid treatment and may mediate its cytotoxic effects. SLAMF1 could be used as a potential therapeutic or diagnostic target (soluble form) for NASH." @default.
- W3172788432 created "2021-06-22" @default.
- W3172788432 creator A5000004058 @default.
- W3172788432 creator A5009386318 @default.
- W3172788432 creator A5014453565 @default.
- W3172788432 creator A5022618012 @default.
- W3172788432 creator A5044191909 @default.
- W3172788432 creator A5056956120 @default.
- W3172788432 creator A5080766322 @default.
- W3172788432 date "2021-05-01" @default.
- W3172788432 modified "2023-10-12" @default.
- W3172788432 title "SLAMF1 Mediates Hepatocyte Death in a Model of Non‐Alcoholic Steatohepatitis" @default.
- W3172788432 doi "https://doi.org/10.1096/fasebj.2021.35.s1.02350" @default.
- W3172788432 hasPublicationYear "2021" @default.
- W3172788432 type Work @default.
- W3172788432 sameAs 3172788432 @default.
- W3172788432 citedByCount "0" @default.
- W3172788432 crossrefType "journal-article" @default.
- W3172788432 hasAuthorship W3172788432A5000004058 @default.
- W3172788432 hasAuthorship W3172788432A5009386318 @default.
- W3172788432 hasAuthorship W3172788432A5014453565 @default.
- W3172788432 hasAuthorship W3172788432A5022618012 @default.
- W3172788432 hasAuthorship W3172788432A5044191909 @default.
- W3172788432 hasAuthorship W3172788432A5056956120 @default.
- W3172788432 hasAuthorship W3172788432A5080766322 @default.
- W3172788432 hasConcept C126322002 @default.
- W3172788432 hasConcept C185592680 @default.
- W3172788432 hasConcept C202751555 @default.
- W3172788432 hasConcept C2776200302 @default.
- W3172788432 hasConcept C2777214474 @default.
- W3172788432 hasConcept C2778772119 @default.
- W3172788432 hasConcept C2779134260 @default.
- W3172788432 hasConcept C2779478299 @default.
- W3172788432 hasConcept C2779936771 @default.
- W3172788432 hasConcept C502942594 @default.
- W3172788432 hasConcept C543025807 @default.
- W3172788432 hasConcept C55493867 @default.
- W3172788432 hasConcept C71924100 @default.
- W3172788432 hasConcept C86803240 @default.
- W3172788432 hasConceptScore W3172788432C126322002 @default.
- W3172788432 hasConceptScore W3172788432C185592680 @default.
- W3172788432 hasConceptScore W3172788432C202751555 @default.
- W3172788432 hasConceptScore W3172788432C2776200302 @default.
- W3172788432 hasConceptScore W3172788432C2777214474 @default.
- W3172788432 hasConceptScore W3172788432C2778772119 @default.
- W3172788432 hasConceptScore W3172788432C2779134260 @default.
- W3172788432 hasConceptScore W3172788432C2779478299 @default.
- W3172788432 hasConceptScore W3172788432C2779936771 @default.
- W3172788432 hasConceptScore W3172788432C502942594 @default.
- W3172788432 hasConceptScore W3172788432C543025807 @default.
- W3172788432 hasConceptScore W3172788432C55493867 @default.
- W3172788432 hasConceptScore W3172788432C71924100 @default.
- W3172788432 hasConceptScore W3172788432C86803240 @default.
- W3172788432 hasFunder F4320321595 @default.
- W3172788432 hasFunder F4320332161 @default.
- W3172788432 hasIssue "S1" @default.
- W3172788432 hasLocation W31727884321 @default.
- W3172788432 hasOpenAccess W3172788432 @default.
- W3172788432 hasPrimaryLocation W31727884321 @default.
- W3172788432 hasRelatedWork W2026169386 @default.
- W3172788432 hasRelatedWork W2036534325 @default.
- W3172788432 hasRelatedWork W2045399735 @default.
- W3172788432 hasRelatedWork W2118285452 @default.
- W3172788432 hasRelatedWork W2255762252 @default.
- W3172788432 hasRelatedWork W2268135223 @default.
- W3172788432 hasRelatedWork W2520935512 @default.
- W3172788432 hasRelatedWork W2596478853 @default.
- W3172788432 hasRelatedWork W4226365321 @default.
- W3172788432 hasRelatedWork W4312196341 @default.
- W3172788432 hasVolume "35" @default.
- W3172788432 isParatext "false" @default.
- W3172788432 isRetracted "false" @default.
- W3172788432 magId "3172788432" @default.
- W3172788432 workType "article" @default.